Separate terms with OR to return results that match either term.
 
Clear All

611 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Enzalutamide Xtandi 40 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 2012 In Use
NA Uridine Triacetate Xuriden 2 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
J9228 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 Jan. 1, 2012 In Use
C9284 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 July 1, 2011 Dec. 31, 2011 No Longer Used
Not yet assigned Axicabtagene Ciloleucel Yescarta consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
C9480 Trabectedin Yondelis 0.1 mg Chemotherapy Alkylating Agent Natural Product No 2015 July 1, 2016 In Use
C9296 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan. 1, 2013 Dec. 31, 2013 No Longer Used
J9400 Ziv-aflibercept Zaltrap 1 mg Chemotherapy Recombinant Fusion Protein VEGF-IgG1 No 2012 Jan. 1, 2014 In Use
J9320 Streptozocin Zanosar 1 g Chemotherapy Alkylating Agent Nitrosourea No 1982 Jan. 1, 1986 In Use
NA Niraparib Zejula 100 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Vemurafenib Zelboraf 240 mg Chemotherapy Enzyme Inhibitor BRAF Yes 2011 In Use
J9223 Lurbinectedin Zepzelca 0.1mg Chemotherapy Alkylating Agent Adduct Forming Agent No 2020 Jan. 1, 2021 In Use
C9117 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct. 1, 2002 Dec. 31, 2002 No Longer Used
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct. 1, 2002 Dec. 31, 2002 No Longer Used
C9058 Pegfilgrastim-bmez Ziextenzo 0.5mg Ancillary Therapy immunomodulatorne Granulocyte Colony Stimulating Factor No 2019 March 31, 2020 July 1, 2020 No Longer Used
Q5120 Pegfilgratim-bmez Ziextenzo 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2019 July 1, 2020 In Use
J1190 Dexrazoxane Zinecard 250 mg Ancillary Therapy Chemoprotective Detoxifying Agent No 1995 Jan. 1, 2007 In Use
Q5118 Bevacizumab-bvcr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct. 1, 2019 In Use
J2405 Ondansetron Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1991 Jan. 1, 1993 In Use
Q0179 Ondansetron Zofran, Zofran ODT, Zuplenz 8 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 April 1, 1998 Dec. 31, 2011 No Longer Used
Q0162 Ondansetron with active chemotherapy treatment adminstration Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2012 In Use
S0181 Ondansetron Zofran, Zofran ODT, Zuplenz 4 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2002 Dec. 31, 2011 No Longer Used
S0119 Ondansetron Zofran, Zofran ODT, Zuplenz 4 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2012 In Use
J9202 Goserelin Acetate Zoladex 3.6 mg Hormonal Therapy GnRH Agonist No 1989 Jan. 1, 1997 In Use
J3487 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 Jan. 1, 2003 Dec. 31, 2013 No Longer Used

Found 611 results in 3 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.